Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press1310.17650/1726-9784-2015-14-2-17-22REVIEWSОБЗОРЫ ЛИТЕРАТУРЫMECHANISMS OF MELANOMA DRUG RESISTANCEМЕХАНИЗМЫ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ МЕЛАНОМЫBaryshnikovaM. A.БарышниковаМ. А.
Russian Federation
AfanasievaD. A.АфанасьеваДарья Андреевна
Russian Federation
danila459@mail.ruUlasovI. V.УласовИ. В.
Russian Federation
BaryshnikovA. Yu.БарышниковА. Ю.
Russian Federation
ФГБНУ «РОНЦ им. Н.Н. Блохина»30062015142172210042018https://bioterapevt.abvpress.ru/jour/article/view/13

Metastatic melanoma is an aggressive skin cancer, which resistant to antitumor drugs. This review describes the different mechanisms of melanoma resistance and approaches to overcoming it.

Метастатическая меланома - агрессивная форма рака кожи, плохо поддающаяся химиотерапии из-за быстрого развития устойчивости к противоопухолевым химиопрепаратам. В обзоре рассмотрены разные механизмы развития резистентности меланомы и существующие подходы к ее преодолению.

меланомалекарственная устойчивостьАВС-транспортерыклеточная гибельmelanomadrug resistanceABC-transporterscell deathСтавровская А.А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток // Биохимия. - 2000. - Т. 65, вып. 1. - С. 112-26.Ставровская А.А., Стромская Т.П. Транспортные белки семейства АВС и множественная лекарственная устойчивость опухолевых клеток // Биохимия. - 2008. - Т. 73, Вып. 5. - С. 735-50.Anvekar R.A., Asciolla J.J., Lopez-Rivera E. et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens // Cell Death and Disease. - 2012. - 3. - e420.Arkenau H.T., KeffordR., Long G.V. Targeting BRAF for patients with melanoma // Br J Cancer. - 2011. - 104. - P. 392-8.Attaoua C., Vincent L.A., Abdel Jaoued A. et al. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids //Fundam Clin Pharmacol. - 2015. - 29(1). - P. 62 - 71.Avery-Kiejda K.A., Bowden N.A., Croft A.J. et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation // BMC Cancer. - 2011. - 11. P. 203.Benjamin C.L., Melnikova V.O., Ananthaswamy H.N. P53 protein and patho-genesis of melanoma and nonmelanoma skin cancer // Adv Exp Med Biol. - 2008. - 624. - P. 265-82.Berger W., Hauptmann E., Elbling L. et al. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells // Int J Cancer. - 1997. - 71. - P. 108-15.Chartrain M., Riond J., Stennevin A. Melanoma chemotherapy leads to selection ABCB5-expressing cells // PloS ONE. - 2012. - 7(5). -e36762.Chen K.G., Valencia J.C., Lai B. et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas // Proc Natl Acad Sci USA. - 2006. - 103. - P. 9903-7.Chen T.C., Cho H.-Y., Wang W. et al. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo // Cancer Letters. - 2015. - 358. - P. 144-51.Colone M., Calcabrini A., Toccacieli L. et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion // J Invest Dermatol. - 2008. - 128. - P. 957-71.De Milito A., Canese R., Marino M.L. et al. pHdependent antitumour activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumour acidity // Int J Cancer. - 2010. - 127. - P. 207-19.Depeille P., Cuq P., Mary S. et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects // Mol Pharmacol. - 2004. - 65(4). - P. 897-905.de Waard N.E., Kolovou P.E., McGuire S.P. et al. Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma // Ocul Oncol Pathol. - 2015. - 1(3). - P. 182-9.Erice O., Smith M.P., White R. et al. MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide // Mol Cancer Ther. -2015. - 14(5). - 1236-46.Federici C., Petrucci F., Caimi S. et al. Exosome Release and Low pH Belong to a Framework of Resistance of HumanMelanoma Cells to Cisplatin // PLoS ONE. - 2014. - 9(2). - e88193.Frank N.Y., Pendse S.S., Lapchak P.H. et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter // J Biol Chem. - 2003. - 278. - P. 47156-65.Frank N.Y., Margaryan A., Huang Y. et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma // Cancer Res.- 2005. - 65. - P. 4320-33.Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics // Nat Rev Cancer. - 2004. - 4(4). - P. 296-307.Glavinas H., Krajcsi P., Cserepes J., Sarkadi B The Role of ABC Transporters in Drug Resistance, Metabolism, and Toxicity // Current Drug Delivery. - 2004. - 1(1). - 1-16.Grichnik J.M., Burch J.A., Schulteis R.D. et al. Melanoma, a tumor based on a mutant stem cell? // J Invest Dermatol. - 2006. - 126. -P. 142-53.Kreiseder B., Holper-Schichl Y.M., Muellauer B. et al. Alpha-Catulin Contributes to Drug-Resistanceof Melanoma by Activating NF-kB and AP-1 // PLoS ONE. - 2015. - 10(3). - e0119402.Legha S.S., Ring S., Bedikian A. et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha // Ann Oncol. - 1996. - 7. - P. 827-35.Liu Y., Xie M., Song T. et al. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1 // Pigment Cell Melanoma Res. - 2014. - 28. - P. 161-70.Luo Y., Ellis L.Z., Dallaglio K. et al. Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance // J Invest Dermatol. - 2012. - 132(10). - P. 2440-50.Matin R.N., Chikh A., Chong S. L.P. et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis // J. Exp. Med. - 2013. - 210(3). - P. 581-603.Molinari A., Toccacieli L., Calcabrini A. et al. Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells // Anticancer Res. - 2000. - 20. - P. 2691-6.Ouar Z., Lacave R., Bens M., Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells // Cell Biol Toxicol. - 1999. - 15. - P. 91-100.Raghunand N., Martı'nez-Zaguila'n R., Wright S.H., Gillies R.J. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs // Biochem Pharmacol. - 1999. - 57. - P. 1047-58.Schadendorf D., Makki A., Stahr C. et al. Membrane transport proteins associated with drug resistance expressed in human melanoma // Am J Pathol. - 1995. - 147. - P. 1545-52.Schatton T., Murphy G.F., Frank N.Y. et al. Identification of cells initiating human melanomas // Nature. - 2008. - 451. - P. 345-9.Shao Y., Aplin A.E. BH3-only protein silencing contributes to acquired resis-tance to PLX4720 in human melanoma // Cell Death Differ. - 2012. - 19. - P. 2029-39.Simon S., Roy D., Schindler M. Intracellular pH and the control of multidrug resistance // Proc Natl Acad Sci USA. - 1994. - 91. - P. 1128-32.Tawbi H.A., Villaruz L., Tarhini A. et al. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours // British Journal of Cancer. - 2011. - 105. - P. 773-7.Ueda Y., Richmond A. NF-kB activation in melanoma // Pigment Cell Res. - 2006. - 19. - Р. 112-24.Wagle N., Emery C., Berger M.F. et al. Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling // J. Clin. Oncol. - 2011. - 29. - P. 3085-96.Walsh N., Kennedy S., Larkin A.M. et al. Membrane transport proteins in human melanoma: associations with tumor aggressiveness and metastasis // Br. J. Cancer. - 2010. - 102. - P. 1157-62.